pharma · Prurigo Nodularis · Vitiligo
Incyte
Incyte is a pharma organization headquartered in Wilmington, USA. Primary therapeutic focus areas include Prurigo Nodularis, Vitiligo, Hidradenitis Suppurativa, Chronic Graft-Versus-Host Disease, chronic graft-versus-hos
Company details
- Status
- Public
- HQ
- 1801 Augustine Cut-Off, Wilmington, Delaware 19803, US
- Employees
- 3,381
- Programs
- 53
- Drugs
- 61
- Patents
- 0
Quick answer
Incyte is a pharma organization headquartered in Wilmington, USA. Primary therapeutic focus areas include Prurigo Nodularis, Vitiligo, Hidradenitis Suppurativa, Chronic Graft-Versus-Host Disease, chronic graft-versus-host disease. NovaPharmaNews links 53 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (29), phase 2 (14), phase 1 (10).
Company snapshot
Incyte maintains 53 tracked programs across Prurigo Nodularis, Vitiligo, Hidradenitis Suppurativa, Chronic Graft-Versus-Host Disease, chronic graft-versus-host disease, Myeloproliferative Neoplasms, Advanced or metastatic solid tumors, Atopic Dermatitis, Advanced Solid Tumors Harboring a KRASG12C Mutation, Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors, Anaemia associated with myel
- 53 active pipeline program(s) linked via ClinicalTrials.gov.
- 53 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Incyte. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- deal
Incyte's Strategic AI Partnerships: Implications for Pharma
Recent coverage
Lilly’s early JAK data raises myelofibrosis competition question
Eli Lilly reported early positive data for a next-generation JAK inhibitor acquired through Ajax. The readout could position Lilly as a potential future competitor to Incyte’s Jakafi in myelofibrosis.
Incyte's Strategic Positioning of Monjuvi for First-Line DLBCL
Incyte is strategically positioning Monjuvi for first-line treatment of DLBCL, responding to the competitive landscape of bispecific therapies. This article delves into the implications for pharmaceutical teams and investors.
PharmaEssentia's Strategic Move: Eric Vogel Joins to Drive Besremi Expansion
PharmaEssentia has appointed Eric Vogel, a former Incyte executive, to spearhead the expansion of its drug Besremi. This strategic move highlights the company's growth ambitions in the pharmaceutical sector.
Incyte's Strategic AI Partnerships: Implications for Pharma
Incyte has signed significant AI deals with Genesis Molecular AI and Edison Scientific, marking a pivotal moment for its innovation strategy. This article explores the implications for the pharmaceutical landscape.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Incyte.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Incyte.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Incyte?
-
Is Incyte publicly traded?
-
What drugs does Incyte develop or market?
-
What are the latest developments for Incyte?
-
What therapeutic areas does Incyte focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.